{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T20:59:56Z","timestamp":1780693196641,"version":"3.54.1"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>\n                      This exploratory study aimed to evaluate the clinical feasibility and added diagnostic value of the heterodimeric agent\n                      <jats:sup>68<\/jats:sup>\n                      Ga-NOTA-3P-TATE-RGD, targeting both SSTR2 and integrin \u03b1\n                      <jats:sub>v<\/jats:sub>\n                      \u03b2\n                      <jats:sub>3<\/jats:sub>\n                      , in patients with radioactive-iodine-negative differentiated thyroid cancer (DTC), through a comparison with\n                      <jats:sup>18<\/jats:sup>\n                      F-FDG PET\/CT.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods:<\/jats:title>\n                    <jats:p>\n                      Twenty-two patients with radioactive-iodine-negative DTC underwent both\n                      <jats:sup>68<\/jats:sup>\n                      Ga-NOTA-3P-TATE-RGD and\n                      <jats:sup>18<\/jats:sup>\n                      F-FDG PET\/CT within 1 week. Diagnostic performance and semiquantitative parameters were compared between the two agents. Based on the collected gene mutation data, a preliminary analysis was conducted on differences in PET uptake among different gene mutation types.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      A total of 265 and 295 lesions were detected on\n                      <jats:sup>68<\/jats:sup>\n                      Ga-NOTA-3P-TATE-RGD and\n                      <jats:sup>18<\/jats:sup>\n                      F-FDG PET\/CT, respectively.\n                      <jats:sup>68<\/jats:sup>\n                      Ga-NOTA-3P-TATE-RGD detected 45 exclusive lesions (12.71%), predominantly in bone (6 lesions) and brain (5 lesions), while\n                      <jats:sup>18<\/jats:sup>\n                      F-FDG identified 75 exclusive lesions in lymph nodes (24 lesions) and lungs (51 lesions). The dual-targeted agent exhibited superior total specificity (92.3% vs 70.6%) and significantly higher tumor-background ratio for bone metastases [3.4 (2.6, 4.0) vs 2.3 (1.6, 2.9),\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.008]. For PET comparison of different gene mutations,\n                      <jats:sup>68<\/jats:sup>\n                      Ga-NOTA-3P-TATE-RGD showed highest uptake in TERT promoter-mutant lesions (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.01), while\n                      <jats:sup>18<\/jats:sup>\n                      F-FDG had maximal uptake in BRAF-mutant lesions (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.01).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>\n                      <jats:sup>68<\/jats:sup>\n                      Ga-NOTA-3P-TATE-RGD PET\/CT is feasible for radioactive-iodine-negative DTC, providing complementary diagnostic information to\n                      <jats:sup>18<\/jats:sup>\n                      F-FDG with enhanced detection of bone and brain metastases. The intense uptake observed in lesions with TERT-associated aggressive subtypes supports potential utility for specific disease identification.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/rlu.0000000000006422","type":"journal-article","created":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T16:00:24Z","timestamp":1775491224000},"page":"570-579","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Dual-targeted 68Ga-NOTA-3P-TATE-RGD PET\/CT in Radioactive-iodine Negative Differentiated Thyroid Cancer"],"prefix":"10.1097","volume":"51","author":[{"given":"Jialin","family":"Xiang","sequence":"first","affiliation":[{"name":"Department of Nuclear Medicine, State Key Laboratory of Complex Severe and Rare Diseases, Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences &Peking Union Medical College, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanwei","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, State Key Laboratory of Complex Severe and Rare Diseases, Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences &Peking Union Medical College, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, State Key Laboratory of Complex Severe and Rare Diseases, Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences &Peking Union Medical College, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2435-8771","authenticated-orcid":false,"given":"Xingtong","family":"Peng","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, State Key Laboratory of Complex Severe and Rare Diseases, Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences &Peking Union Medical College, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-0457-5455","authenticated-orcid":false,"given":"Cong","family":"Shi","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, State Key Laboratory of Complex Severe and Rare Diseases, Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences &Peking Union Medical College, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2448-2441","authenticated-orcid":false,"given":"Rongxi","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, State Key Laboratory of Complex Severe and Rare Diseases, Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences &Peking Union Medical College, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiarou","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, State Key Laboratory of Complex Severe and Rare Diseases, Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences &Peking Union Medical College, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5558-0829","authenticated-orcid":false,"given":"Di","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Peking University People\u2019s Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqing","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua Medicine, Tsinghua University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaona","family":"Jin","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, State Key Laboratory of Complex Severe and Rare Diseases, Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences &Peking Union Medical College, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yansong","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, State Key Laboratory of Complex Severe and Rare Diseases, Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences &Peking Union Medical College, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9931-850X","authenticated-orcid":false,"given":"Zhaohui","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, State Key Laboratory of Complex Severe and Rare Diseases, Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences &Peking Union Medical College, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,3,24]]},"reference":[{"key":"R1-20260605","first-page":"7","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA A Cancer J Clinicians"},{"key":"R2-20260605","doi-asserted-by":"crossref","first-page":"3859","DOI":"10.1007\/s00259-025-07222-1","article-title":"Chinese management guidelines for radioactive iodine-refractory differentiated thyroid cancer (2025 edition)","volume":"52","author":"Lin","year":"2025","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R3-20260605","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/nrendo.2011.142","article-title":"Molecular genetics and diagnosis of thyroid cancer","volume":"7","author":"Nikiforov","year":"2011","journal-title":"Nat Rev Endocrinol"},{"key":"R4-20260605","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1089\/thy.2024.0486","article-title":"A clinical nomogram to predict survival outcomes in patients with well-differentiated thyroid cancer","volume":"35","author":"Valero","year":"2025","journal-title":"Thyroid\u00ae"},{"key":"R5-20260605","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s12943-025-02263-4","article-title":"Reprogramming of thyroid cancer metabolism: from mechanism to therapeutic strategy","volume":"24","author":"Wan","year":"2025","journal-title":"Mol Cancer"},{"key":"R6-20260605","doi-asserted-by":"crossref","first-page":"225","DOI":"10.7150\/ijbs.75459","article-title":"HIF-1\u03b1\/YAP signaling rewrites glucose\/iodine metabolism program to promote papillary thyroid cancer progression","volume":"19","author":"Song","year":"2023","journal-title":"Int J Biol Sci"},{"key":"R7-20260605","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1093\/annonc\/mdz400","article-title":"Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"30","author":"Filetti","year":"2019","journal-title":"Ann Oncol"},{"key":"R8-20260605","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1007\/s00259-024-06930-4","article-title":"[68Ga]Ga-LNC1007 versus 2-[18F]FDG in the evaluation of patients with metastatic differentiated thyroid cancer: a head-to-head comparative study","volume":"52","author":"Chen","year":"2025","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R9-20260605","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1148\/radiol.212430","article-title":"68Ga fibroblast activation protein inhibitor PET\/CT in the detection of metastatic thyroid cancer: comparison with 18F-FDG PET\/CT","volume":"304","author":"Fu","year":"2022","journal-title":"Radiology"},{"key":"R10-20260605","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1530\/EJE-22-0072","article-title":"FDG PET\/CT in differentiated thyroid cancer patients with low thyroglobulin levels","volume":"187","author":"Lebbink","year":"2022","journal-title":"Eur J Endocrinol"},{"key":"R11-20260605","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1089\/thy.2019.0450","article-title":"68Ga-DOTA-RGD2 positron emission tomography\/computed tomography in radioiodine refractory thyroid cancer: prospective comparison of diagnostic accuracy with 18F-FDG positron emission tomography\/computed tomography and evaluation toward potential theranostics","volume":"30","author":"Parihar","year":"2020","journal-title":"Thyroid"},{"key":"R12-20260605","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/s41598-017-19036-9","article-title":"Clinical value of 99mTc-3PRGD2 SPECT\/CT in differentiated thyroid carcinoma with negative 131I whole-body scan and elevated thyroglobulin level","volume":"8","author":"Gao","year":"2018","journal-title":"Sci Rep"},{"key":"R13-20260605","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.2967\/jnumed.112.107821","article-title":"Integrin \u03b1v \u03b23 imaging of radioactive iodine\u2013refractory thyroid cancer using 99mTc-3PRGD2","volume":"53","author":"Zhao","year":"2012","journal-title":"J Nucl Med"},{"key":"R14-20260605","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1007\/s00259-024-06944-y","article-title":"PET\/CT imaging of differentiated and medullary thyroid carcinoma using the novel SSTR-targeting peptide [18F]SiTATE \u2013 first clinical experiences","volume":"52","author":"Kunte","year":"2025","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R15-20260605","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1097\/RLU.0000000000005366","article-title":"68Ga-DOTATATE PET\/CT versus 18F-FDG PET\/CT in TENIS syndrome: a head-to-head comparison with elevated and suppressed TSH levels in papillary thyroid carcinoma\u2014a pilot study","volume":"49","author":"Almeida","year":"2024","journal-title":"Clin Nucl Med"},{"key":"R16-20260605","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1007\/s00259-016-3378-5","article-title":"68Ga]DOTATATE PET\/MRI and [18F]FDG PET\/CT are complementary and superior to diffusion-weighted MR imaging for radioactive-iodine-refractory differentiated thyroid cancer","volume":"43","author":"Vrachimis","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R17-20260605","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1158\/1078-0432.CCR-20-3453","article-title":"177Lu-DOTA-EB-TATE, a radiolabeled analogue of somatostatin receptor type 2, for the imaging and treatment of thyroid cancer","volume":"27","author":"Thakur","year":"2021","journal-title":"Clin Cancer Res"},{"key":"R18-20260605","doi-asserted-by":"crossref","first-page":"4218","DOI":"10.1007\/s00259-022-05852-3","article-title":"A prospective head-to-head comparison of 68 Ga-NOTA-3P-TATE-RGD and 68Ga-DOTATATE in patients with gastroenteropancreatic neuroendocrine tumours","volume":"49","author":"Jiang","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R19-20260605","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1097\/RLU.0000000000002680","article-title":"Evaluation of lung cancer and neuroendocrine neoplasm in a single scan by targeting both somatostatin receptor and integrin \u03b1v\u03b23","volume":"44","author":"Zheng","year":"2019","journal-title":"Clin Nucl Med"},{"key":"R20-20260605","doi-asserted-by":"crossref","first-page":"115094","DOI":"10.1016\/j.bmc.2019.115094","article-title":"Preclinical evaluation of a dual sstr2 and integrin \u03b1v\u03b23-targeted heterodimer [68Ga]-NOTA-3PEG4-TATE-RGD","volume":"27","author":"Liu","year":"2019","journal-title":"Bioorg Med Chem"},{"key":"R21-20260605","doi-asserted-by":"crossref","first-page":"3938","DOI":"10.1007\/s00259-025-07271-6","article-title":"[18F]FAPI- 04 PET\/CT for pathologic response assessment in pancreatic cancer patients with systemic treatment","volume":"52","author":"Li","year":"2025","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R22-20260605","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-022-09839-z","article-title":"Comparative evaluation of somatostatin and CXCR4 receptor expression in different types of thyroid carcinoma using well-characterised monoclonal antibodies","author":"Czajkowski","year":"2022","journal-title":"BMC Cancer"},{"key":"R23-20260605","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1089\/thy.2005.15.1011","article-title":"Differential pattern of integrin receptor expression in differentiated and anaplastic thyroid cancer cell lines","volume":"15","author":"Hoffmann","year":"2005","journal-title":"Thyroid"},{"key":"R24-20260605","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1530\/ERC-13-0210","article-title":"Highly prevalent TERT promoter mutations in aggressive thyroid cancers","volume":"20","author":"Liu","year":"2013","journal-title":"Endocr Relat Cancer"},{"key":"R25-20260605","doi-asserted-by":"crossref","first-page":"23719","DOI":"10.1038\/s41598-024-75087-9","article-title":"TERT promoter mutations contribute to adverse clinical outcomes and poor prognosis in radioiodine refractory differentiated thyroid cancer","volume":"14","author":"Tan","year":"2024","journal-title":"Sci Rep"},{"key":"R26-20260605","doi-asserted-by":"crossref","first-page":"7186","DOI":"10.1158\/1078-0432.CCR-09-1425","article-title":"Combination of hTERT knockdown and IFN-\u03b3 treatment inhibited angiogenesis and tumor progression in glioblastoma","volume":"15","author":"George","year":"2009","journal-title":"Clin Cancer Res"},{"key":"R27-20260605","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1089\/thy.2011.0401","article-title":"The BRAF V600E mutation in papillary thyroid carcinoma is associated with glucose transporter 1 overexpression","volume":"22","author":"Grabellus","year":"2012","journal-title":"Thyroid"},{"key":"R28-20260605","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1186\/s13046-020-01757-x","article-title":"The molecular and gene\/miRNA expression profiles of radioiodine resistant papillary thyroid cancer","volume":"39","author":"Colombo","year":"2020","journal-title":"J Exp Clin Cancer Res"},{"key":"R29-20260605","doi-asserted-by":"crossref","first-page":"177","DOI":"10.2967\/jnumed.119.227652","article-title":"The genetic duet of BRAF V600E and TERT promoter mutations robustly predicts loss of radioiodine avidity in recurrent papillary thyroid cancer","volume":"61","author":"Liu","year":"2020","journal-title":"J Nucl Med"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000006422","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T20:00:15Z","timestamp":1780689615000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000006422"}},"subtitle":["An Exploratory Comparative Study With 18F-FDG"],"short-title":[],"issued":{"date-parts":[[2026,3,24]]},"references-count":29,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000006422","relation":{},"ISSN":["0363-9762","1536-0229"],"issn-type":[{"value":"0363-9762","type":"print"},{"value":"1536-0229","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,24]]},"assertion":[{"value":"2025-12-10","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-18","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}